CCAAT/enhancer-binding protein α antagonizes transcriptional activity of hypoxia-inducible factor 1 α with direct protein - Protein interaction

Carcinogenesis

Volumn 29, Issue 2, 2008, Pages 291-298

  Yang, L ^a   Jiang, Y ^a   Wu, S F ^a   Zhou, M Y ^a   Wu, Y L ^a   Chen, G Q ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CCAAT ENHANCER BINDING PROTEIN ALPHA; GLUCOSE TRANSPORTER 1; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LUCIFERASE; PHOSPHOGLYCERATE KINASE; SHORT HAIRPIN RNA; VASCULOTROPIN;

ARTICLE; CANCER INHIBITION; CELL STRAIN U937; CONTROLLED STUDY; ENZYME ASSAY; GENE TARGETING; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; CERCOPITHECUS AETHIOPS; COS CELLS; DNA; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RNA; TRANS-ACTIVATION (GENETICS); U937 CELLS;

EID: 40549130675     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm262     Document Type: Article

References (52)

1. Semenza,G.L. (2006) Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1. Exp. Physiol. 91, 803-406.
2. Melillo,G. (2006) Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res., 4, 601-605.
3. Minet,E. et al. (2000) Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis [review]. Int. J. Mol. Med., 5, 253-259.
4. Ohh,M. et al. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol., 2, 423-427.
5. Maxwell,P.H. et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271-275.
6. Jaakkola,P. et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 292, 468-472.
7. Jeong,J.W. et al. (2002) Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell, 111, 709-720.
8. Li,F. et al. (2007) Regulation of HIF-1a1pha stability through S-nitrosylation. Mol. Cell, 26, 63-74.
9. Semenza,G.L. (2000) HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol., 88 1474-1480.
10. Xue,Z.H. et al. (2005) Metavanadate suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia-inducible factor-1alpha protein. Biochem. Biophys. Res. Commun., 332, 1140-1145.
11. Jiang,Y. et al. (2005) Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia, 19, 1239-1247.
12. Huang,Y. et al. (2003) Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: Possible mediation of hypoxia-inducible factor-1alpha. Leukemia, 17, 2065-2073.
13. Liu,W. et al. (2006) Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood, 107, 698-707.
14. Nguyen-Khac,F. et al. (2006) Functional analyses of the TEL-ARNT fusion protein underscores a role for oxygen tension in hematopoietic cellular differentiation. Oncogene, 25, 4840-4847.
15. Song,L. et al. (2007) Hypoxia-inducible factor-1a-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene, Jul 16: [Epub ahead of print].
16. Kim,J.S. et al. (2006) Effects of Tiron, 4,5-dihydroxy-1,3-benzene disulfonic acid, on human promyelotic HL-60 leukemia cell differentiation and death. Toxicology, 223, 36-45.
17. Radomska,H.S. et al. (1998) CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol. Cell Biol., 18, 4301-4314.
18. Ramji,D.P. et al. (2002) CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J., 365, 561-575.
19. Schuster,M.B. et al. (2006) C/EBPalpha: A tumour suppressor in multiple tissues? Biochim. Biophys. Acta, 1766, 88-103.
20. Ema,M. et al. (1997) A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl Acad. Sci. USA, 94, 4273-4278.
21. Semenza,G.L. et al. (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol., 12, 5447-5454.
22. Zhao,K.W. et al. (2004) Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: Its role in leukemic cell differentiation. Blood, 104, 3731-3738.
23. Holmquist-Mengelbier,L. et al. (2006) Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell, 10, 413-423.
24. Lauzier,M.C. et al. (2006) [HIF-1 activation during tumor progression: Implications and consequences]. Bull. Cancer, 93 349-356.
25. Jiang,B.H. et al. (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem., 271, 17771-17778.
26. Ehrismann,D. et al. (2007) Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem. J., 401, 227-234.
27. Minet,E. et al. (1999) Hypoxia-induced activation of FHF-1: Role of HIF-1alpha-Hsp90 interaction. FEBS Lett., 460, 251-256.
28. Kaidi,A. et al. (2007) Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat. Cell Biol., 9, 210-217.
29. Wenger,R.H. et al. (2005) Integration of oxygen signaling at the consensus HRE. Sci. STKE., 2005, re12.
30. Koshiji,M. et al. (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J., 23, 1949-1956.
31. Zhang,H. et al. (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell, 11, 407-420.
32. Nagamura-Inoue,T. et al. (2001) Transcription factors that regulate growth and differentiation of myeloid cells. Int. Rev. Immunol., 20, 83-105.
33. Rosenbauer,F. et al. (2007) Transcription factors in myeloid development: Balancing differentiation with transformation. Nat. Rev. Immunol., 7, 105-117.
34. Petrovick,M.S. et al. (1998) Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol. Cell Biol., 18, 3915-3925.
35. Saunthararajah,Y. et al. (2006) Combinatorial action of RUNX1 and PU.1 in the regulation of hematopoiesis. Crit. Rev. Eukaryot. Gene Expr., 16, 183-192.
36. Zhang,D.E. et al. (1996) CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol. Cell Biol., 16, 1231-1240.
37. Kurokawa,M. et al. (2003) Role of AML1/Runx1 in the pathogenesis of hematological malignancies. Cancer Sci., 94, 841-846.
38. Koschmieder,S. et al. (2005) Role of transcription factors C/ EBPalpha and PU.1 in normal hematopoiesis and leukemia. Int. J. Hematol., 81, 368-377.
39. Chen,G.Q. et al. (2006) Hypoxia inducible factor-1 alpha and leukemic cell differentiation. Sheng Li Xue Bao, 58, 5-13.
40. Peng,Z.G. et al. (2007) Acute myeloid leukemia-1 antagonizes transcriptional activity of hypoxia inducible factor-1a protein through direct protein-protein interaction. Oncogene, Aug 6: [Epub ahead of print].
41. Naoe,T. et al. (1999) Relationship between degradation of PML-RARalpha and differentiation. Blood, 94, 1478-1479.
42. Bernardi,R. et al. (2006) PML inhibits HIF-1alpha translation and neo-angiogenesis through repression of mTOR. Nature, 442, 779-785.
43. Goda,N. et al. (2003) HIF-1 in cell cycle regulation, apoptosis, and tumor progression. Antioxid. Redox Signal., 5, 467-473.
44. Powis,G. et al. (2004) Hypoxia inducible factor-1alpha as a cancer drug target. Mol. Cancer Ther., 3, 647-654.
45. Talks,K.L. et al. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157, 411-421.
46. Zhong,H. et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res., 59, 5830-5835.
47. Patiar,S. et al. (2006) Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat. Cancer, 13 (suppl. 1), S61-S75.
48. Costa,D.B. et al. (2007) Immunohistochemical analysis of C/ EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590. Lung Cancer, 56, 97-103.
49. Tomizawa,M. et al. (2002) Decreased expression of the CCAAT/ enhancer binding protein alpha gene involved in hepatocyte proliferation in human hepatocellular carcinomas. Int. J. Mol. Med., 9, 597-600.
50. Shim,M. et al. (2005) Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation. Cancer Res., 65, 861-867.
51. Gery,S. et al. (2005) Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin. Cancer Res., 11, 3184-3190.
52. Tada,Y. et al. (2006) Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J. Natl Cancer Inst., 98, 396-406.